RxDoctor Payments DataLook up a doctor →

Terra Kamp, NP

Nurse Practitioner · Jacksonville, NCNPI 1083079701

Payments from drug & device makers

$72,004in general payments, 2019–2025

Across 623 payments — averaging $115.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$37K
  • Pfizer$26K
  • Axsome Therapeutics, Inc.$3K
  • Novartis$854
  • EMD Serono, Inc.$556
  • Lundbeck LLC$547
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$3,4505%
  • Speaking & faculty fees$58,12981%
  • Travel & lodging$1,6912%
  • Food & beverage$8,59712%
  • Education$1380%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,004 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,052
Medicare patients
74
Services billed
10,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina145$200,434
Nurtec OdtRimegepant Sulfate104$156,396
Kesimpta PenOfatumumab11$131,898
QuliptaAtogepant64$86,982
Ajovy AutoinjectorFremanezumab-Vfrm55$69,186
InbrijaLevodopa13$63,528
Emgality PenGalcanezumab-Gnlm51$60,856
UbrelvyUbrogepant36$58,081
SprixKetorolac Tromethamine13$33,857
Aimovig AutoinjectorErenumab-Aooe26$31,944
ReyvowLasmiditan Succinate38$27,749
Ajovy SyringeFremanezumab-Vfrm13$8,830
QuviviqDaridorexant Hcl17$8,249
Sumatriptan Succinate59$3,003
Eletriptan HbrEletriptan Hydrobromide18$2,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$36,817$345,497245 claims
PfizerNurtec Odt$26,401$156,396104 claims
Acorda Therapeutics, IncInbrija$195$63,52813 claims
Lilly USA, LLCReyvow$102$27,74938 claims
Idorsia Pharmaceuticals US IncQuviviq$25$8,24917 claims
Upsher-smith Laboratories LLCTopiramate$13$46050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Jacksonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →